Focused On-demand Library for Mitochondrial genome maintenance exonuclease 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.







Alternative names:


Alternative UPACC:

Q9BQP7; B2RDG5; D3DW29; Q96SW3


Mitochondrial genome maintenance exonuclease 1, encoded by the gene with accession number Q9BQP7, plays a crucial role in mitochondrial DNA (mtDNA) maintenance. It exhibits metal-dependent single-stranded DNA exonuclease activity, favoring 5'-3' exonuclease activity, and is also capable of endonuclease activity on linear substrates. This protein is essential for maintaining proper 7S DNA levels and is likely involved in mtDNA repair processes, including the processing of Okazaki fragments and DNA flaps.

Therapeutic significance:

Mitochondrial DNA depletion syndrome 11, a disorder characterized by progressive external ophthalmoplegia, muscle weakness, and respiratory insufficiency, is associated with variants affecting this gene. Understanding the role of Mitochondrial genome maintenance exonuclease 1 could open doors to potential therapeutic strategies for this syndrome, highlighting its importance in mitochondrial disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.